Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 4.9    
    

Execution
Version 

 
 

License Agreement    
    

        Effective as of August 1, 2003 ("EFFECTIVE DATE"), GENETIC TECHNOLOGIES LIMITED, having an office at 60
Hanover Street, Fitzroy, Victoria 3065, Australia ("GTG") and QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation having an office at One Malcolm
Avenue, Teterboro, NJ 07608, USA ("LICENSEE"), agree as follows: 

ARTICLE I
 BACKGROUND  

	1.1
	GTG
represents that it owns certain proprietary and intellectual property rights pertaining to intron sequence analysis in respect to which it is prepared to grant the rights and
licenses provided for herein to LICENSEE.

	1.2
	Without
admitting that the LICENSED PATENTS are valid or that LICENSEE's performance of the LICENSED SERVICES or LICENSED THIRD PARTY SERVICES infringes the LICENSED PATENTS, LICENSEE
wishes to acquire licenses under and to obtain access to GTG's proprietary and intellectual property rights in order to commercialize certain diagnostic testing services and kits useful for such
services. 

ARTICLE II
 GENERAL DEFINITIONS AND RELATIONSHIPS AMONG DEFINITIONS  

	2.1
	"AGREEMENT"
means this document, its attachments, all addenda, schedules, exhibits, appendices, and any amendments to the foregoing.

	2.2
	"CONFIDENTIAL
INFORMATION" means any and all information which is disclosed by either party to the other verbally, electronically, visually, or in a written or other tangible form
which is either identified or should be reasonably understood to be confidential or proprietary. CONFIDENTIAL INFORMATION includes, but is not limited to, the specific terms and/or conditions of this
AGREEMENT, trade secrets, ideas, processes, formulas, programs, software, source of supply, technology, discoveries, developments, inventions, techniques, marketing plans, strategies, forecasts,
unpublished financial statements, prices, costs, and customer lists.

	2.3
	"EXCLUDED
FIELD" means genetic analysis using or based upon, in whole or in part, the genotyping of more than one hundred thousand (100,000) putative single nucleotide polymorphisms,
such polymorphisms found in three (3) or more chromosomes of the relevant organism.

	2.4
	"EXCLUSION
TIME PERIOD" means the period from the EFFECTIVE DATE until August 31, 2006.

	2.5
	"FIELD
OF USE" means, during the EXCLUSION TIME PERIOD, gene-based diagnostic service testing for humans, other than the EXCLUDED FIELD, and upon expiration of the
EXCLUSION TIME PERIOD means gene-based diagnostic service testing for humans without limitation.

	2.6
	GTG
and LICENSEE are hereunder commonly referred to as "parties" (in singular and plural usage, as required by the context).

	2.7
	"LICENSED
PATENT(S)" means United States Patent No. 5,612,179 ("the '179 Patent") and United States Patent No. 5,096,557 and all reissues, reexaminations, divisionals,
continuations, 

1

 

continuations-in-part,
substitutions, and extensions of the '179 Patent, applications therefore, and patents which may issue upon such applications, and foreign counterparts of
the foregoing. 

	2.8
	"LICENSED
SERVICES" means diagnostic service testing (i) developed by LICENSEE or on behalf of LICENSEE; (ii) performed by LICENSEE or a SUBSIDIARY of LICENSEE;
(iii) that is not on behalf of a third party national testing laboratory that performs gene-based diagnostic testing; and (iv) that but for the license granted herein would
infringe or contribute to the infringement of one or more claims of a LICENSED PATENT. For the avoidance of doubt, it is understood and agreed that "third party national testing laboratory" does not
include hospitals.

	2.9
	"LICENSED
THIRD PARTY SERVICES" means diagnostic service testing (i) developed by LICENSEE or on behalf of LICENSEE; (ii) performed by LICENSEE or a SUBSIDIARY of
LICENSEE; (iii) on behalf of a third party national testing laboratory that performs gene-based diagnostic testing; and (iv) that but for the license granted herein would
infringe or contribute to the infringement of one or more claims of a LICENSED PATENT. For the avoidance of doubt, it is understood and agreed that "third party national testing laboratory" does not
include hospitals.

	2.10
	"PUBLIC
HEALTH CRISIS" means an urgent situation in which the health status of an area within the TERRITORY is adversely affected. PUBLIC HEALTH CRISIS includes localized outbreaks
of an infectious disease or a potential outbreak of an infectious disease that has a reasonable possibility of occurring and that poses a significant threat to a community or region in the TERRITORY.
PUBLIC HEALTH CRISIS shall also mean those circumstances in which third party national testing laboratories (as used in Sections 2.8 and 2.9 above) seek LICENSED THIRD PARTY SERVICES from LICENSEE
because of regulatory issues affecting such third party national testing laboratory.

	2.11
	"SUBSIDIARY"
means any corporation, company or other legal entity, in which more than fifty percent (50%) of the shares entitled to vote for the election of directors or persons
performing similar functions are, now or hereafter, owned or controlled, directly or indirectly by a party hereto, or jointly by the parties hereto; provided, however, that any corporation, company or
other legal entity shall be a SUBSIDIARY only for as long as such ownership or control exists. For purposes of LICENSEE, SUBSIDIARY shall be deemed to include Sonora Quest Laboratories and any other
LICENSEE joint ventures which meet the definition of SUBSIDIARY set forth in this Article 2.9.

	2.12
	"TERRITORY"
means Canada, Mexico and the United States of America.

	2.13
	"TERM"
means the life of the last expiring VALID PATENT CLAIM, except as otherwise provided in Article VII.

	2.14
	"VALID
PATENT CLAIM" shall mean any claim in a filed and unabandoned patent application or unexpired patent with the LICENSED PATENTS, which claim has not been held unpatentable,
unenforeceable, or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been
finally abandoned or admitted to be invalid or unenforeceable through reissue, disclaimer or otherwise. 

ARTICLE III
 RELEASE  

        Subject to the terms and conditions set forth herein, GTG agrees that, providing LICENSEE fully and faithfully discharges the obligation to pay the license issue
fee, GTG will release LICENSEE from all claims, demands, and rights of action which GTG may have as of the EFFECTIVE DATE relating to LICENSED SERVICES on account of infringement of any LICENSED
PATENT prior to the EFFECTIVE DATE to the extent the acts constituting such infringement would be licensed hereunder. 

2

 

ARTICLE IV
 GRANT TO LICENSEE  

	4.1
	Subject
to the terms and conditions of this AGREEMENT, GTG hereby grants and agrees to grant to LICENSEE, during the TERM of this AGREEMENT:

	(i)
	A
non-exclusive, non-assignable, annual fee-bearing license under the LICENSED PATENTS (without the right to sublicense except to LICENSEE's
SUBSIDIARIES) to perform, use, sell, and offer to sell LICENSED SERVICES in the FIELD OF USE solely within the TERRITORY; and

	(ii)
	A
revocable, limited, non-exclusive, non-assignable, license under the LICENSED PATENTS (without the right to sublicense except to LICENSEE's SUBSIDIARIES) to
perform, use, sell, and offer to sell LICENSED THIRD PARTY SERVICES in the FIELD OF USE solely within the TERRITORY and only in response to a PUBLIC HEALTH CRISIS and for no longer than such PUBLIC
HEALTH CRISIS reasonably requires.

	4.2
	The
license granted to LICENSEE under Article 4.1(ii) is revocable unilaterally by GTG upon ten (10) days advanced written notice to LICENSEE if GTG has a
reasonable belief that such license is being used to assist an unlicensed third party avoid obtaining its own license under the LICENSED PATENTS. Should GTG initiate a revocation under this
Article 4.2, the parties agree to negotiate in good faith regarding appropriate terms and conditions under which LICENSEE shall be granted a license under the LICENSED PATENTS for purposes of
providing LICENSED THIRD PARTY SERVICES.

	4.3
	The
rights and licenses granted by GTG in this AGREEMENT are personal to LICENSEE. Except as set forth in Section 4.4 and Section 11.10, LICENSEE shall not assign or
otherwise transfer (by operation of law or otherwise) any license or right granted hereunder or any interest therein, without the prior written consent of GTG (which may be withheld in GTG's sole and
absolute discretion). Any attempted assignment or transfer without such prior written consent shall be void and shall upon written notice by GTG terminate all rights of LICENSEE under this AGREEMENT.

	4.4
	LICENSEE
may extend the license granted under this AGREEMENT to its SUBSIDIARIES provided that LICENSEE ensures that such SUBSIDIARIES are bound to the terms and conditions of this
AGREEMENT as the same apply to LICENSEE. 

ARTICLE V
 CONSIDERATION  

	5.1
	As
partial consideration for the release of Article III and the licenses granted by this AGREEMENT, LICENSEE agrees to pay to GTG a non-refundable license issue fee
of one hundred thousand United States Dollars ($100,000.00) on or before August 30, 2003.

	5.2
	As
additional consideration for the rights and licenses granted by this AGREEMENT, LICENSEE agrees to pay to GTG an annual payment of fifty thousand United States Dollars ($50,000.00)
payable commencing on the first (1st) anniversary of the EFFECTIVE DATE and annually on each subsequent anniversary of the EFFECTIVE DATE for the TERM and the prorated amount calculated
from the EFFECTIVE DATE of the last year of the TERM to the expiration date the following year of the LICENSED PATENTS, such annual payments representing annual fees in lieu of royalties. 

3

 
	5.3
	All
payments required under this AGREEMENT shall be sent by electronic wire transfer to: 

Key Bank

#307070267

1130 Haxton Drive

Fort Collins, Colorado 80525

Account: Genetic Technologies Limited

Account Number: 76009 000 2576

	5.4
	LICENSEE
agrees to pay interest of five percent (5%) per year or the maximum rate allowed by law, whichever is less, on fees payable but not paid to GTG when due.

	5.5
	MATERIAL
BREACH: Breach of any provision of this Article V or part thereof shall be deemed a material breach. 

ARTICLE VI
 WAIVER  

        No waiver by either party, express or implied, of any breach of any term, condition, or obligation of this AGREEMENT by the other party shall be construed as a
waiver of any subsequent breach of that term, condition, or obligation, or of any other term, condition, or obligation of this AGREEMENT of the same or different nature. 

ARTICLE VII
 TERM AND TERMINATION OF AGREEMENT  

	7.1
	This
AGREEMENT shall extend from the EFFECTIVE DATE hereof for the TERM, unless terminated earlier as provided below.

	7.2
	Either
party shall have the right to terminate this AGREEMENT upon any material breach of any term or condition of this AGREEMENT by the other party, which has not been corrected
within thirty (30) days after receipt of a notice in writing with reference to this Article 7.2 and such termination shall be without prejudice to any other rights or claims the
aggrieved party may have against the other party. Termination shall not affect any obligation owed by either party to the other prior to the termination. Either party shall have the right to terminate
this AGREEMENT in the event that the other party shall become involved in insolvency, dissolution, bankruptcy, or receivership proceedings affecting the operation of its business, or in the event that
the other party discontinues business for any reason.

	7.3
	LICENSEE
shall have the right to terminate this AGREEMENT upon thirty (30) days written notice to GTG.

	7.4
	SURVIVAL:
Articles II, III, VIII and X shall survive the termination of this AGREEMENT. 

ARTICLE VIII
 CONFIDENTIALITY, PUBLICITY AND PRESS RELEASES  

	8.1
	DISCLOSURE
AND USE: The parties agree that the terms and conditions set forth in this AGREEMENT are CONFIDENTIAL INFORMATION. The CONFIDENTIAL INFORMATION disclosed by the parties
("Disclosing Party") to another party ("Receiving Party") constitutes the confidential and proprietary information of the Disclosing Party and the Receiving Party agrees to treat all CONFIDENTIAL
INFORMATION of the other in the same manner as it treats its own similar proprietary information, but in no case will the degree of care be less than reasonable care. The Receiving Party shall use
CONFIDENTIAL INFORMATION of the Disclosing Party only in performing under this AGREEMENT and shall retain the CONFIDENTIAL INFORMATION in 

4

 

confidence
and not disclose to any third party (except as authorized under this AGREEMENT) without the Disclosing Party's express written consent. The Receiving Party shall disclose the Disclosing
Party's CONFIDENTIAL INFORMATION only to those employees and contractors of the Receiving Party who have a need to know such information for the purposes of this AGREEMENT, and such employees and
contractors must have entered into agreements with the Receiving Party containing confidentiality provisions covering the CONFIDENTIAL INFORMATION, or similar confidential information, with terms and
conditions at least as restrictive as those set forth herein. 

	8.2
	PERMITTED
USE AND DISCLOSURES: Each party hereto may use or disclose CONFIDENTIAL INFORMATION disclosed to it by the other party to the extent such use or disclosure is reasonably
necessary in prosecuting or defending litigation, complying with applicable law, stock exchange rules, governmental regulation or court order, submitting information to tax or other governmental
authorities, or otherwise exercising its rights hereunder.

	8.3
	EXCEPTIONS:
Notwithstanding the foregoing, each party's confidentiality obligations hereunder shall not apply to information which:

	(i)
	is
already known to the Receiving Party prior to disclosure by the Disclosing Party;

	(ii)
	becomes
publicly available without fault of the Receiving Party;

	(iii)
	is
rightfully obtained by the Receiving Party from a third party without restriction as to disclosure, or is approved for release by written authorization of the Disclosing Party;

	(iv)
	is
developed independently by the Receiving Party without use of or access to the Disclosing Party's CONFIDENTIAL INFORMATION; or

	(v)
	is
required to be disclosed by law or governmental regulation, provided that the Receiving Party provides reasonable notice to Disclosing Party of such required disclosure and
reasonably cooperates with the Disclosing Party in limiting such disclosure.

	8.4
	PUBLICITY
AND PRESS RELEASES: The parties must mutually agree upon any media/press releases with regard to the existence of this AGREEMENT. The parties shall discuss issuing such a
press release after the execution of this AGREEMENT, but are not obligated to issue such a release.

	8.5
	Neither
party shall issue any other press releases or other public statements relating to this AGREEMENT without prior written approval of the other party; provided however, that the
parties shall be permitted to make disclosures of information submitted to a stock exchange pursuant to Article 8.2 or as required by applicable laws or regulations.

	8.6
	The
parties agree that any breach of this AGREEMENT may cause irreparable harm to the Disclosing Party. Therefore, the Disclosing Party shall have, in addition to any rights and
remedies available at law, the right to seek specific performance of this AGREEMENT. 

5

 
ARTICLE IX
 NOTICE  

	9.1
	Any
notice, request or statement hereunder shall be deemed to be sufficiently given or rendered when personally delivered, delivered by a major commercial rapid delivery courier
service or mailed by certified or registered mail, return receipt requested, and if given or rendered to LICENSEE, addressed to: 

Quest
Diagnostics Incorporated

Attn: General Counsel

One Malcolm Avenue

Teterboro, New Jersey 07608

USA 

or,
if given or rendered to GTG, addressed to: 

Dr. Mervyn
Jacobson

Executive Chairman

Genetic Technologies Limited

60 Hanover Street

Fitzroy, Victoria 3065

Australia 

with
a copy to: 

Michael
A. DeSanctis, Esq.

Faegre & Benson LLP

3200 Wells Fargo Center

1700 Lincoln Street

Denver, CO 80203

USA 

or,
in any case, to such changed address or person as GTG or LICENSEE shall have specified to the other by written notice. 

ARTICLE X
 REPRESENTATIONS AND WARRANTIES  

	10.1
	GTG
represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT and grant to LICENSEE the license and
other rights as set forth herein, and there are no outstanding grants, licenses, encumbrances, liens, or agreements, entered into by GTG, either written or implied, inconsistent therewith or pursuant
to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default.

	10.2
	GTG
represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of GTG.

	10.3
	To
the best of GTG's knowledge as of the EFFECTIVE DATE, utilization of the claimed methods in the LICENSED PATENTS does not (i) necessitate infringement of the valid
intellectual property rights of any third party; or (ii) require the payment of any royalties or other amounts to any third party, except for PCR or other genomic DNA amplification
methodologies.

	10.4
	LICENSEE
represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT, and there are no outstanding grants,
licenses, encumbrances, liens, or agreements, entered into by LICENSEE, either written or 

6

 

implied,
inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default. 

	10.5
	LICENSEE
represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of LICENSEE.

	10.6
	INDEMNIFICATION
BY LICENSEE: LICENSEE agrees to hold GTG harmless from any claims by third parties arising from the performance, use, sale, and offer for sale of LICENSED SERVICES by
LICENSEE, and LICENSEE shall indemnify, hold harmless, and defend GTG, and GTG's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents against any and all claims, causes
of action, demands, judgments, settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs (collectively, "LOSSES") arising out of or in connection with:
(i) the use, performance, sale or offer for sale of LICENSED SERVICES; (ii) any breach by LICENSEE of any representation, warranty, or covenant hereunder, or (iii) the failure of
LICENSEE to perform any covenants or obligations contained in this AGREEMENT. This indemnity shall exclude LOSSES to the extent such LOSSES are attributable to the willful misconduct or gross
negligence of GTG.

	10.7
	INDEMNIFICATION
BY GTG: GTG agrees to indemnify, hold harmless, and defend LICENSEE, and LICENSEE's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or
agents against any and all LOSSES arising out of or in connection with (i) any breach by GTG of any representation, warranty or covenant hereunder; or (ii) the failure of GTG to perform
any covenants or obligations contained in this AGREEMENT. This indemnity shall exclude LOSSES to the extent such LOSSES are attributable to the willful misconduct or gross negligence of LICENSEE.

	10.8
	DISCLAIMER
OF WARRANTIES: Except as expressly set forth herein, EACH PARTY EXPRESSLY DISCLAIMS, TO THE EXTENT ALLOWED BY APPLICABLE LAW, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS
OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE (EVEN IF INFORMED OF SUCH PURPOSE), NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.

	10.9
	LIMITATION
OF LIABILITY: EXCEPT FOR BREACH OF PAYMENT TERMS UNDER ARTICLE V OR FOR LIABILITY FOR BREACH OF ARTICLE VIII OR BREACH OF SECTION 10.3, NEITHER PARTY SHALL BE ENTITLED TO
RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER.

	10.10
	Nothing
contained in this AGREEMENT shall be construed as:

	(i)
	a
warranty or representation by GTG as to the validity or scope of any LICENSED PATENT; or

	(ii)
	a
warranty or representation that any manufacture, sale, lease, use or other disposition hereunder will be free from infringement of patents other than those under which and to the
extent to which licenses are in force hereunder; or

	(iii)
	an
agreement to bring or prosecute actions or suits against third parties for infringement or conferring any right to bring or prosecute actions or suits against third parties for
infringement; or 

7

 

	(iv)
	conferring
any right to use by either party, in advertising, publicity, or otherwise, any trademark, trade name or name, or any contraction, abbreviation or simulation thereof, of
the other party; or

	(v)
	conferring
by implication, estoppel or otherwise, upon LICENSEE, any license or other right under any intellectual property or patent, except that expressly granted hereunder. 

ARTICLE XI
 MISCELLANEOUS  

	11.1
	SERVICE
LITERATURE: To the extent practicable, LICENSEE will prominently display on any literature or other materials (in paper, electronic or other format) distributed with or about
any LICENSED SERVICE, a notice indicating that the LICENSED SERVICE is provided pursuant to a license from GTG under the LICENSED PATENTS, which patents are owned by GTG.

	11.2
	COPIES
OF LITERATURE: From time to time LICENSEE will provide GTG with copies of literature, bulletins, and other customer materials, such as copies of web pages or other electronic
information used in connection with LICENSED SERVICES, with the exact items to be provided to GTG to be determined at LICENSEE's discretion.

	11.3
	NO
ASSISTANCE TO THIRD PARTIES: LICENSEE agrees that it will not knowingly induce, encourage, or assist any third party in connection with attacking the title or right of GTG in and
to the LICENSED PATENTS or attacking the validity or enforceability of the LICENSED PATENTS.

	11.4
	CONSTRUCTION:
This AGREEMENT has been negotiated by the parties and their respective counsel. This AGREEMENT shall be interpreted fairly in accordance with its terms and without any
strict construction in favor of or against either party. This AGREEMENT shall not be construed in favor or against either party by reason of the authorship of any provisions hereof. The existence or
absence of any term or condition of this AGREEMENT shall not be used in the construction or interpretation of any other agreement between the parties. The existence or absence of any term or condition
of any other agreement between the parties shall not be used in the construction or interpretation of this AGREEMENT.

	11.5
	NOTICE
REGARDING INFRINGEMENT: LICENSEE shall promptly notify GTG of any third party that it reasonably believes based on specific evidence to be infringing a LICENSED PATENT, and
will use reasonable efforts to provide to GTG any non-confidential information it has in support of such belief. LICENSEE agrees to use its commercially reasonable best efforts to
cooperate, at GTG's expense, with GTG in any action for infringement of a LICENSED PATENT brought by GTG.

	11.6
	MARKINGS:
To the extent practicable, LICENSEE shall use markings as GTG may reasonably request from time to time, including, but not limited to, marking the LICENSED SERVICES and/or
documentation related thereto with patent number(s).

	11.7
	MODIFICATION:
This AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter of this AGREEMENT and merges all prior discussions between
the parties, and no one of the parties shall be bound by any modification of this AGREEMENT, or by any conditions, definitions, warranties, or representations with respect to the subject matter of
this AGREEMENT, other than as expressly provided for herein, or as duly set forth on or subsequent to the EFFECTIVE DATE in writing and signed by duly authorized representatives of the party to be
bound thereby.

	11.8
	CHOICE
OF LAW: This AGREEMENT and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance with the laws of
the State of Delaware (excluding conflicts of laws) and of the United States. 

8

 
	11.9
	FORUM
SELECTION: The venue for any controversy or claim arising out of or in connection with this AGREEMENT shall be any court of competent jurisdiction.

	11.10
	ASSIGNMENT.
Neither party may assign this AGREEMENT without the prior written consent of the other party except in the event of the sale of all or substantially all of a party's
capital stock, business or assets whether by merger or otherwise pertaining to the subject matter of this AGREEMENT, such party may assign this AGREEMENT to its successor and shall provide notice of
such assignment to the other party; provided however, that prior to any assignment permitted herein by LICENSEE, its successor must expressly assume in writing LICENSEE's obligations under this
AGREEMENT and expressly acknowledge in writing that products and services of such successor existing prior to such assignment shall not be LICENSED SERVICES.

	11.11
	ATTORNEYS'
FEES: Upon resolution of any claim or controversy arising under this AGREEMENT, the prevailing party shall be awarded its reasonable attorneys' fees and costs in addition
to any other amount awarded.

	11.12
	INDEPENDENT
BUSINESS: The parties acknowledge that their business operations are completely independent and nether party shall at any time hold itself out as an agent or
representative of the other party. No partnership, joint venture, or other relationship shall be deemed to exist by virtue of this AGREEMENT.

	11.13
	INDEPENDENT
TERMS: All the terms of this AGREEMENT shall be independent and unconditional so that the performance of any one term shall not be subject to any set off or
counterclaim.

	11.14
	SEVERABILITY:
In the event any clause or term of this AGREEMENT is determined to be void, invalid, or unenforceable, the clause shall be stricken to the extent necessary in order to
overcome the limitation and as revised this AGREEMENT shall remain in full force and effect.

	11.15
	HEADINGS:
The headings contained within this AGREEMENT are for convenience and reference purposes only. They do not form a part hereof and shall not affect the meaning or
interpretation of this AGREEMENT.

	11.16
	FURTHER
ASSURANCES: The parties hereto shall execute such further documents and perform such further acts as may be necessary to comply with the terms of this AGREEMENT and
consummate the transactions herein provided.

	11.17
	FORCE
MAJEURE: Neither party shall be held responsible if the fulfillment of any terms or provisions of this AGREEMENT are delayed or prevented by wars, revolutions, fires, floods,
acts of God, acts of terrorism whether actual or threatened, or other causes similar to those enumerated and not within the control of the party whose performance is interfered with, and which by the
exercise of reasonable diligence, the party is unable to prevent.

	11.18
	COUNTERPARTS:
This AGREEMENT may be executed in counterparts (and evidenced by facsimile signatures), each of which will be deemed an original and all of which together constitute
one instrument. 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

9

 

IN
WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this AGREEMENT. 

	GTG:	 	LICENSEE:
	
Genetic Technologies Limited	
 	
Quest Diagnostics Incorporated
	

By	

    
	
 	

By	

    

	

    
 Printed Name	
 	

    
 Printed Name
	

    
 Title	
 	

    
 Title

10

QuickLinks

Exhibit 4.9

License AgreementQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 4.10    
    

 
 

LICENSE AGREEMENT    
    

        This License Agreement ("AGREEMENT"), effective this 31st day of December, 2003 ("EFFECTIVE DATE"), is by and between  GENETIC TECHNOLOGIES
LIMITED and its AFFILIATES, having an office at 60 Hanover Street, Fitzroy, Victoria 3065, Australia ("GTG") and  TM BIOSCIENCE CORPORATION and its AFFILIATES, having an office at
439 University Avenue, Suite 1050, Toronto, Ontario, M5G 1Y8, Canada
(collectively the "LICENSEE"). 

ARTICLE I
 BACKGROUND

        1.1   LICENSEE
wishes to acquire a right and license to practice certain patents of GTG, subject to the terms and conditions of this AGREEMENT. 

        1.2   GTG
is prepared to grant a non-exclusive license to LICENSEE under certain patents, subject to the terms and conditions of this AGREEMENT. 

ARTICLE II
 GENERAL DEFINITIONS AND RELATIONSHIPS AMONG DEFINITIONS

        2.1   "AFFILIATE"
shall mean any legal entity (such as a corporation, partnership, or limited liability company) which directly or indirectly controls, is controlled by, or is
under common control with either party or its successors or assigns, or any successor or assign of such an entity. For the purposes of this definition, the term "control" means (i) beneficial
ownership of at least fifty percent (50%) of the voting securities of a corporation or other business organization with voting securities or (ii) a fifty percent (50%) or greater interest in
the net assets or profits of a partnership or other business organization without voting securities. 

        2.3   "CONFIDENTIAL
INFORMATION" means any and all information contained in this AGREEMENT, or relating to correspondence or communications (whether verbal, electronic, visual
or written) disclosed in the negotiation of this AGREEMENT, including without limitation all payment and royalty terms. 

        2.4   "EXCLUDED
FIELD" means genetic analysis using or based upon, in whole or in part, the genotyping of more than one hundred thousand (100,000) putative single nucleotide
polymorphisms, such polymorphisms found in three (3) or more chromosomes of the relevant organism. 

        2.5   "EXCLUSION
TIME PERIOD" means the period from the EFFECTIVE DATE until August 31, 2006. 

        2.6   "FIELD
OF USE" means, during the EXCLUSION TIME PERIOD, human genetic testing and diagnostic products outside of the EXCLUDED FIELD, and upon expiration of the EXCLUSION
TIME PERIOD means, human genetic testing and diagnostic products without limitation. 

        2.7   GTG
and LICENSEE may hereunder each be referred to as a "party" and are hereunder commonly referred to as "parties" (in singular and plural usage, as required by the
context). 

        2.8   "LICENSED
PATENT" means the United States patents and patent applications, and other national and foreign patents and patent applications listed in Appendix "A" attached
to this AGREEMENT and all foreign counterpart patents and patent applications thereto (including future counterparts to the patents and patent applications listed in Appendix "A"), all reissues,
reexaminations, divisionals, continuations, continuations-in-part, substitutions and extensions of the foregoing, and any 

1

 

patent
which issues or is granted based on an application which claims as a priority any document, whether or not abandoned or expired, which is also claimed as a priority by any of the foregoing. 

        2.9   "LICENSED
PRODUCT(S)" means products manufactured by or on behalf of LICENSEE and designed by or on behalf of LICENSEE that but for the license granted herein would
infringe or contribute to the infringement of one or more VALID CLAIMS of a LICENSED PATENT, and for clarity does not include products which are manufactured and/or designed by LICENSEE as a third
party contract manufacturer/developer. 

        2.10 "TERM"
means from the EFFECTIVE DATE until the expiration or abandonment of the last-to-expire LICENSED PATENT, except as otherwise provided in
Article VII. 

        2.11 "TERRITORY"
means worldwide. 

        2.12 "VALID
CLAIM(S)" means a claim or claims of an issued or granted patent within the LICENSED PATENT which has not lapsed, became abandoned or been declared invalid or
unenforceable by a court of competent jurisdiction or an administrative agency from which no appeal can be or is taken. 

ARTICLE III
 RELEASE & NON-ADMISSION

        3.1   GTG
hereby releases, acquits and forever discharges LICENSEE from any and all claims, demands, liability and rights of action which GTG may have on the EFFECTIVE DATE on
account of any infringement of any LICENSED PATENT, by LICENSEE's performance or acts that occurred prior to the EFFECTIVE DATE. 

        3.2   Nothing
in this AGREEMENT constitutes or may be construed as, an admission, statement, declaration or other evidence, without limitation, concerning any product of
LICENSEE in relation to LICENSED PATENT. In particular, nothing in this AGREEMENT constitutes an admission by LICENSEE that any current or future product of LICENSEE whether in commercial use,
development or planned for development, will infringe any claim of the LICENSED PATENT or that any such claim is valid or enforceable in any jurisdiction worldwide. 

ARTICLE IV
 GRANT TO LICENSEE

        4.1   Subject
to the terms and conditions of this AGREEMENT, GTG hereby grants LICENSEE, during the TERM of this AGREEMENT, a nonexclusive, non-transferable
(except as provided herein), annual fee-bearing, irrevocable license under the LICENSED PATENT (without the right to sublicense) to make, have made, use, sell, offer for sale, and import
LICENSED PRODUCTS in the FIELD OF USE throughout the TERRITORY. 

        4.2   The
rights and licenses granted by GTG in this AGREEMENT are personal to LICENSEE and LICENSEE shall not assign or otherwise transfer any license or right granted
hereunder or any interest therein except as contemplated in Section 11.6. 

        4.3   Without
limiting the patent exhaustion rights under the law, the rights and licenses to use, re-sell, distribute, import or export granted to LICENSEE in
this AGREEMENT shall extend to all customers, users and/or purchasers of LICENSED PRODUCTS from LICENSEE (whether directly or indirectly). 

        4.4   All
rights not explicitly granted to LICENSEE are reserved by GTG. Not limiting the foregoing, LICENSEE acknowledges that it is not granted any rights to any other
patents or other intellectual property rights of GTG or any third party. 

2

 

ARTICLE V
 CONSIDERATION

        5.1   As
partial consideration for the release of Article III and the licenses granted by this AGREEMENT, LICENSEE agrees to pay to GTG a non-refundable
license fee of one-hundred thousand United States Dollars (US $100,000), payable in four (4) equal installments of twenty-five thousand United States Dollars (US
$25,000) and due on the EFFECTIVE DATE, April 1, 2004, July 1, 2004, and October 1, 2004, respectively. 

        5.2   As
additional consideration for the rights and licenses granted by this AGREEMENT, LICENSEE agrees to pay to GTG for the TERM an annual royalty on the LICENSED PRODUCTS
of fifty thousand United States Dollars (US $50,000) on or before the anniversary date of the EFFECTIVE DATE of this AGREEMENT which represents an annual fee in lieu of royalties. No other sums or
royalties shall be due GTG, its successors, assigns and/or legal representatives as a result of this AGREEMENT or the license hereunder. 

        5.3   All
fees payable hereunder by LICENSEE to GTG shall be sent by electronic wire transfer to: 

Key
Bank

#307070267

1130 Haxton Drive

Fort Collins, Colorado 80525

Account: Genetic Technologies Limited

Account Number: 76009 000 2576 

        5.4   LICENSEE
agrees to pay interest of ten percent (10%) per year or the maximum rate allowed by law, whichever is less, on annual fees payable but not paid to GTG when due. 

        5.5   All
fees payable hereunder by LICENSEE are payable to GTG's successors, heirs, or assigns, as appropriate. 

ARTICLE VI
 WAIVER

        6.1   No
waiver by either party, express or implied, of any breach of any term, condition, or obligation of this AGREEMENT by the other party shall be construed as a waiver of
any subsequent breach of that term, condition, or obligation, or of any other term, condition, or obligation of this AGREEMENT of the same or different nature. 

ARTICLE VII
 TERM AND TERMINATION OF AGREEMENT

        7.1   This
AGREEMENT shall be in effect for the TERM, unless terminated earlier as provided herein. 

        7.2   Either
party shall have the right to terminate this AGREEMENT upon any material breach of any term or condition of this AGREEMENT by the other party, which has not been
corrected within thirty (30) days after receipt of a notice in writing with reference to this Section 7.2 and such termination shall be without prejudice to any other rights or claims
the aggrieved party may have against the other party. GTG shall have the right to terminate this AGREEMENT in the event that LICENSEE shall become involved in dissolution or in the event that LICENSEE
entirely discontinues business for any reason, excepting in the event that business is discontinued as a result of the sale of all or substantially all of LICENSEE's capital stock, business or assets
as contemplated in Section 11.6. 

3

 

        7.3   LICENSEE
shall have the right to terminate this AGREEMENT for any reason or no reason upon thirty (30) days written notice to GTG; after which period LICENSEE
shall have no further obligations to make royalty payments to GTG under this AGREEMENT. 

        7.4   Termination
or expiration of this AGREEMENT shall not affect any obligation owed by LICENSEE to GTG prior to the termination or expiration. Upon termination or
expiration of this AGREEMENT for any reason whatsoever: 

        7.4.1 All
rights granted to LICENSEE hereunder shall revert to GTG and LICENSEE shall immediately cease all activities authorized by this AGREEMENT; 

        7.4.2 LICENSEE
shall pay GTG the pro-rated amount of the annual payment set forth in Section 5.2 that had accumulated as of the date of termination or
expiration for that year of the AGREEMENT. 

        7.4.3 LICENSEE
shall have no further obligations to make royalty payments to GTG under this AGREEMENT. 

        7.5   SURVIVAL:
Articles II, III, VIII, IX and XI, Section 7.4 and all payment obligations incurred prior to termination or expiration shall survive the termination or
expiration of this AGREEMENT. 

ARTICLE VIII
 CONFIDENTIALITY, PUBLICITY AND PRESS RELEASES

        8.1   LIMITATIONS
ON USE AND DISCLOSURE: The parties agree that as regards the CONFIDENTIAL INFORMATION, each party is both a receiving party ("RECEIVING PARTY") and a
disclosing party ("DISCLOSING PARTY"). The parties agree to treat all CONFIDENTIAL INFORMATION in the same manner as it treats its own similar proprietary information, but in no case will the degree
of care be less than reasonable care. The RECEIVING PARTY shall use CONFIDENTIAL INFORMATION of the DISCLOSING PARTY only in performing under this AGREEMENT and shall retain the CONFIDENTIAL
INFORMATION in confidence and not disclose to any third party (except as authorized under this AGREEMENT) without the DISCLOSING PARTY's express written consent. The RECEIVING PARTY shall disclose the
DISCLOSING PARTY's CONFIDENTIAL INFORMATION only to those employees and contractors of the RECEIVING PARTY who have a need to know such information for the purposes of this AGREEMENT, and such
employees and contractors must have entered into agreements with the RECEIVING PARTY containing confidentiality provisions covering the CONFIDENTIAL INFORMATION, or similar confidential information,
with terms and conditions at least as restrictive as those set forth herein. Notwithstanding the foregoing, each party's confidentiality obligations hereunder shall not apply to information which as
evidenced by written records: 

        8.1.1   is
already known to the RECEIVING PARTY, without an obligation of confidentiality, prior to disclosure by the DISCLOSING PARTY; 

        8.1.2   becomes
publicly available without fault of the RECEIVING PARTY; 

        8.1.3   is
rightfully obtained by the RECEIVING PARTY from a third party without restriction as to disclosure, or is approved for release by written
authorization of the DISCLOSING PARTY; or 

        8.1.4   is
developed independently by the RECEIVING PARTY without use of or access to the DISCLOSING PARTY's CONFIDENTIAL INFORMATION. 

4

 

        8.2   PERMITTED
USE AND DISCLOSURE: Each party hereto is permitted to disclose this AGREEMENT and use or disclose the CONFIDENTIAL INFORMATION disclosed to it by the other
party: 

        8.2.1   To
the extent such use or disclosure is reasonably necessary in connection with complying with any public stock exchange or securities rules; or 

        8.2.2   To
its legal and/or financial advisors, provided such advisors maintain the confidentiality of this AGREEMENT; or 

        8.2.3   To
the extent such use or disclosure is reasonably necessary in prosecuting or defending litigation, complying with applicable law, governmental
regulation or court order, submitting information to tax or other governmental authorities, or otherwise exercising its rights hereunder; or 

        8.2.4   To
the extent necessary to enforce its rights under this AGREEMENT in connection with a legal proceeding or as required to be disclosed by law or
governmental regulation. 

        8.2.5   In
the instances set forth in Sections 8.2.3 or 8.2.4, the RECEIVING PARTY shall provide reasonable advance written notice to DISCLOSING PARTY of such
disclosure and reasonably cooperate with the DISCLOSING PARTY in limiting such disclosure. 

        8.3   NON-PUBLICITY:
For clarity, no media/press release shall be prepared by either party relating to this AGREEMENT, except in accordance with
Section 8.2. In all circumstances, where the existence of this AGREEMENT must be disclosed, parties shall make every effort to prevent disclosure of the contents or terms of this AGREEMENT, or
any portion thereof. 

        8.3.1   Any
other disclosure shall be permitted only with the express written consent of the parties, which may be declined at such party's sole discretion. 

ARTICLE IX
 REPRESENTATIONS AND WARRANTIES

        9.1   GTG
represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT and has the sole and
exclusive power and authority to grant to LICENSEE the license and other rights as set forth herein, and there are no outstanding agreements, grants, licenses, encumbrances, liens, or agreements,
either written or implied, inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default. 

        9.2   GTG
represents and warrants that it has the sole and exclusive power and authority to prosecute and enforce the LICENSED PATENT worldwide, except for the authority to
enforce the LICENSED PATENT within the EXCLUDED FIELD during the EXCLUSION TIME PERIOD. 

        9.3   GTG
represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of
GTG. 

        9.4   GTG
represents and warrants that GTG owns and/or controls no other intellectual property rights, other than the LICENSED PATENT, to which a right or a license is
required from GTG for the manufacture, use, sale, importation, exportation, distribution or other commercialization of products of LICENSEE, including without limitation the LICENSED PRODUCTS. In
addition, GTG hereby covenants not to sue and agrees not to assert against LICENSEE and customers, users and/or purchasers of LICENSED PRODUCTS from LICENSEE (whether directly or indirectly), in
respect of LICENSED PRODUCTS, any such intellectual property right that is not included in this AGREEMENT. 

5

 

        9.5   LICENSEE
represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT. 

        9.6   LICENSEE
represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part
of LICENSEE. 

        9.7   INDEMNIFICATION:

        9.7.1   BY
LICENSEE: LICENSEE agrees to hold GTG harmless from any claims by third parties and shall indemnify, hold harmless, and defend GTG, and GTG's
subsidiaries, affiliates, officers, directors, representatives, or employees, against any and all claims, causes of action, demands, judgments,
settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of or in connection with any breach by LICENSEE of any representation, warranty,
or covenant hereunder. 

        9.7.2   BY
GTG: GTG shall defend, indemnify and hold harmless LICENSEE, and LICENSEE's subsidiaries, affiliates, officers, directors, representatives, or
employees against any and all claims, causes of action, demands, judgments, settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of or
in connection with any breach by GTG of any representation, warranty, or covenant hereunder. 

        9.7.3.   The
indemnifying party's indemnification obligations under this Section 9.7 are conditioned upon the indemnified party (a) giving prompt
notice of the claim to the indemnifying party; (b) granting sole control of the defense or settlement of the claim or action to the indemnifying party; and (c) providing reasonable
cooperation to the indemnifying party and, at the indemnifying party's request and expense, assistance in the defense or settlement of the claim. 

        9.8   DISCLAIMER
OF WARRANTIES: EXCEPT AS EXPRESSLY SET FORTH HEREIN, WITH REGARD TO THE LICENSED PATENT, GTG EXPRESSLY DISCLAIMS, TO THE EXTENT ALLOWED BY APPLICABLE LAW, ANY
AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE (EVEN IF INFORMED OF SUCH PURPOSE),
NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO. 

        9.9   LIMITATION
OF LIABILITY: TO THE GREATEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, WITH RESPECT TO ANY CAUSE OF ACTION RELATING TO OR ARISING FROM THIS AGREEMENT (WHETHER
UNDER THIS ARTICLE IX OR OTHERWISE), NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY
LICENSE GRANTED HEREUNDER. 

        9.10 Except
as expressly provided in this AGREEMENT, nothing contained in this AGREEMENT shall be construed as: 

        9.10.1   a
warranty or representation by GTG as to the validity or scope of the LICENSED PATENT except as provided expressly herein; 

        9.10.2   a
warranty or representation that any use or performance contemplated herein will be free from infringement of patents other than the LICENSED PATENTS
under which and to the extent to which licenses are in force hereunder; 

6

 

        9.10.3   an
agreement to bring or prosecute actions or suits against third parties for infringement or conferring any right to bring or prosecute actions or
suits against third parties for infringement; 

        9.10.4   conferring
any right to use by either party, in advertising, publicity, or otherwise, any trademark, trade name or name, or any contraction,
abbreviation or simulation thereof, of the other party, except where expressly stated otherwise; 

        9.10.5   conferring
by implication, estoppel or otherwise, upon LICENSEE, any license or other right under any intellectual property or patent, except that
expressly granted hereunder. 

ARTICLE X
 NOTICE

        10.1 Any
notice, request or statement hereunder shall be deemed to be sufficiently given or rendered when personally delivered, delivered by a major commercial rapid
delivery courier service or mailed by certified or registered mail, return receipt requested, and if given or rendered to LICENSEE, addressed to: 

Richard
Janeczko, Ph.D.

Chief Scientific Officer

Tm Bioscience Corporation

439 University Avenue, Suite 1050

Toronto, Ontario M5G 1Y8

Canada 

        or,
if given or rendered to GTG, addressed to: 

Dr. Mervyn
Jacobson

Executive Chairman

Genetic Technologies Limited

60 Hanover Street

Fitzroy, Victoria 3065

Australia 

        with
a copy to: 

Michael
A. DeSanctis, Esq.

Faegre & Benson LLP

3200 Wells Fargo Center

1700 Lincoln Street

Denver, CO 80203

USA 

or,
in any case, to such changed address or person as GTG or LICENSEE shall have specified to the other by written notice. 

ARTICLE XI
 MISCELLANEOUS

        11.1 CONSTRUCTION:
This AGREEMENT has been negotiated by the parties and their respective counsel. This AGREEMENT shall be interpreted fairly in accordance with its terms
and without any strict construction in favor of or against either party. This AGREEMENT shall not be construed in favor or against either party by reason of the authorship of any provisions hereof.
The 

7

 

existence
or absence of any term or condition of this AGREEMENT shall not be used in the construction or interpretation of any other agreement between the parties. 

        11.2 MARKINGS:
LICENSEE shall display on materials provided with LICENSED PRODUCTS, such as packaging, literature or instructions (in paper, electronic or other format), a
notice indicating relevant LICENSED PATENTS. 

        11.3 EQUITABLE
REMEDIES: Each party acknowledges and agrees that the other party may seek any available remedy, whether in law or equity, upon the other party's breach of
any of its obligations set forth in Article VIII. 

        11.4 MODIFICATION:
This AGREEMENT including its Appendices sets forth the entire agreement and understanding between the parties as to the subject matter of this AGREEMENT
and merges all prior discussions between the parties, and no one of the parties shall be bound by any modification of this AGREEMENT, or by any conditions, definitions, warranties, or representations
with respect to the subject matter of this AGREEMENT, other than as expressly provided for herein, or as duly set forth on or subsequent to the EFFECTIVE DATE in writing and signed by duly authorized
representatives of the party to be bound thereby. 

        11.5 CHOICE
OF LAW: This AGREEMENT and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance
with the laws of the State of New York and of the United States of America. 

        11.6 ASSIGNMENT:
Neither party may assign this AGREEMENT without the prior written consent of the other party, except in the event of the sale of all or substantially all of
a party's capital stock, business, or assets, whether by merger or otherwise pertaining to the subject matter of this AGREEMENT, such party may assign this AGREEMENT to its successor and shall provide
notice of such assignment to the other party; provided however, that prior to any assignment permitted herein by LICENSEE, LICENSEE's successor must expressly assume in writing LICENSEE's obligations
under this AGREEMENT and expressly acknowledge in writing that products of such successor existing prior to such assignment shall not be LICENSED PRODUCTS. 

        11.7 GOVERNING
DOCUMENT: This AGREEMENT may be translated into languages other than English for the convenience of the parties hereto provided, however, the English language
version of this AGREEMENT shall be the governing version and shall not be affected by the interpretation of any other language versions. 

        11.8 INDEPENDENT
BUSINESS: The parties acknowledge that their business operations are completely independent and nether party shall at any time hold itself out as an agent
or representative of the other party. No partnership, joint venture, or other relationship shall be deemed to exist by virtue of this AGREEMENT. 

        11.9 INDEPENDENT
TERMS: All the terms of this AGREEMENT shall be independent and unconditional so that the performance of any one term shall not be subject to any set off or
counterclaim. 

        11.10 SEVERABILITY:
In the event any clause or term of this AGREEMENT is determined to be void, invalid, or unenforceable, the clause shall be reformed to the extent
necessary in order to overcome the limitation and give effect to the original intent and economic effect of the original provision and, as revised this AGREEMENT shall remain in full force and effect. 

        11.11 HEADINGS:
The headings contained within this AGREEMENT are for convenience and reference purposes only. They do not form a part hereof and shall not affect the
meaning or interpretation of this AGREEMENT. 

8

 

        11.12 FURTHER
ASSURANCES: The parties hereto shall execute such further documents and perform such further acts as may be necessary to comply with the terms of this
AGREEMENT and consummate the transactions herein provided. 

        11.13 FORCE
MAJEURE: Neither party shall be held responsible if the fulfillment of any terms or provisions of this AGREEMENT are delayed or prevented by wars, revolutions,
fires, floods, acts of God, acts of terrorism whether actual or threatened, or other causes similar to those enumerated and not within the control of the party whose performance is interfered with,
and which by the exercise of reasonable diligence, the party is unable to prevent. 

        11.14 COUNTERPARTS:
This AGREEMENT may be executed in counterparts (and evidenced by facsimile signatures), each of which will be deemed an original and all of which
together constitute one instrument. 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

9

 

        IN
WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this AGREEMENT. 

	GTG:	 	LICENSEE:
	

Genetic Technologies Limited	
 	

Tm Bioscience Corporation
	

By:	

 	
 	

By:	

 
	 	 	
	 	 	

	 	Dr. Mervyn Jacobson

Executive Chairman	 	 	Dr. Richard Janeczko

Chief Scientific Officer

10

  

 
 

Appendix "A"
  
    Licensed Patents

United
States Patent No. 5,612,179

US Patent 5,192,659

US Patent 5,789,568

US Patent 5,851,762

US Patent 5,069,557 

PATENT
FAMILY:

AUSTRIA (AT)

    Patent (No,Kind,Date): AT 144797 E 19961115

        VERFAHREN ZUM NACHWEIS VON BENACHBARTEN UND ENTFERNT LOKALISIERTEN

            ALLELEN ALS HAPLOTYPEN MITTELS INTRONSEQUENZANALYSE (German)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A    19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): EP 90309107 A 19900820

        Addnl Info: 00414469 19961030

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: German 

	AUSTRIA (AT)

    Legal Status (No,Type,Date,Code,Text):
	 	 	AT 144797	 	R 19961115 AT REF    CORRESPONDS TO EP-PATENT

(ENTSPRICHT EP-PATENT)

EP 414469 P 19961030
	 	 	AT 144797	 	R 19970615 AT UEP    PUBLICATION OF TRANSLATION

OF EUROPEEN PATENT SPECIFICATION

(UEBERSETZUNG DER EUROPAEISCHEN PATENTSCHRIFT

AUSGEGEBEN)
	 	 	AT 144797	 	R 20030915 AT EEIH    CHANGE IN THE PERSON OF

PATENT OWNER (AENDERUNG IN DER PERSON DES

INHABERS)

AUSTRALIA
(AU)

    Patent (No,Kind,Date): AU 9061319 A1 19910228

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

        LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE A G

        Author (Inventor): SIMONS MALCOLM J

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): AU 9061319 A 19900824

        IPC: * C12Q-001/68; C12N-009/22; C12N-015/12; C12P-019/34; G01N-033/50

        Language of Document: English

    Patent (No,Kind,Date): AU 9472850 A1 19941124

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

11

 

            LOCUS
ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG 

Author
(Inventor): SIMONS MALCOLM J

    Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

    Applic (No,Kind,Date): AU 9472850 A 19940908

    IPC: * C12Q-001/68; C12N-015/11

    CA Abstract No: * 115(07)066222Y

    Derwent WPI Acc No: * C 91-059664

    Language of Document: English

Patent (No,Kind,Date): AU 654111 B2 19941027    INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

    LOCUS ALLELES AS HAPLOTYPES (English)

    Patent Assignee: GENETYPE AG

    Author (Inventor): SIMONS MALCOLM J

    Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

    Applic (No,Kind,Date): AU 9061319 A 19900824

    IPC: * C12Q-001/68; C12N-009/22; C12N-015/12; C12P-019/34; G01N-033/50

    CA Abstract No: * 115(07)066222Y

    Derwent WPI Acc No: * C 91-059664

    Language of Document: English

Patent (No,Kind,Date): AU 672519 B2 19961003

    INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

        LOCUS ALLELES AS HAPLOTYPES (English)

    Patent Assignee: GENETYPE AG

    Author (Inventor): SIMONS MALCOLM J

    Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

    Applic (No,Kind,Date): AU 9472850 A 19940908

    IPC: * C12Q-001/68; C12N-015/11

    CA Abstract No: * 115(07)066222Y

    Derwent WPI Acc No: * C 91-059664

Language of Document: English 

CANADA
(CA)

    Patent (No,Kind,Date): CA 2023888 AA 19910226

        INTROL SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English; French)

        Patent Assignee: SIMONS MALCOLM J (AU)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): CA 2023888 A 19900823

        National Class: * D3195000112 M; 15000085 S

        IPC: * C07H-021/00; C12Q-001/68

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English 

12

 

GERMAN
DEMOCRATIC REPUBLIC (DD)

    Patent (No,Kind,Date): DD 299319 A5 19920409

        INTRONSEQUENZANALYSEVERFAHREN ZUM NACHWEIS VON BENACHBARTEN UND

            ENTFERNTEN GENORTALLELEN ALS HAPLOTYPEN (German)

    Patent Assignee: GENETYPE A G (CH)

    Author (Inventor): SIMONS MALCOLM J (AU)

    Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

    Applic (No,Kind,Date): DD 343632 A 19900824

    IPC: * C12Q-001/68

    CA Abstract No: * 115(07)066222Y

    Derwent WPI Acc No: * C 91-059664

    Language of Document: German

GERMAN DEMOCRATIC REPUBLIC (DD)

    Legal Status (No,Type,Date,Code,Text): 

	 	 	DD 299319	 	P 20030213 DD RPI    CHANGE IN THE PERSON, NAME

OR ADDRESS OF THE PATENTEE (SEARCHES

ACCORDING TO ART. 11 AND 12 EXTENSION ACT)

(AENDERUNG IN DER PERSON, IM NAMEN ODER IM

WOHNORT DES INHABERS (RECHERCHEN GEMAESS PAR.

11 UND 12 ERSTRECKUNGSGESETZ))

Genetic Technologies Limited, Fitzroy,

Victoria 3065, AU
	 	 	DD 299319	 	P 20030213 DD RPV    CHANGE IN THE PERSON, THE

NAME OR THE ADDRESS OF THE REPRESENTATIVE

(SEARCHES ACCORDING TO ART. 11 AND 12

EXTENSION ACT) (AENDERUNG IN DER PERSON, IM

NAMEN ODER IM WOHNORT DES VERTRETERS

(RECHERCHEN GEMAESS PAR. 11 UND 12

ERSTRECKUNGSGESETZ))

Patentanwalt Dr. Peter Barz, 80803 M nchen

GERMANY
(DE)

    Patent (No,Kind,Date): DE 69029018 C0 19961205

        VERFAHREN ZUM NACHWEIS VON BENACHBARTEN UND ENTFERNT LOKALISIERTEN

            ALLELEN ALS HAPLOTYPEN MITTELS INTRONSEQUENZANALYSE (German)

    Patent Assignee: GENETYPE AG (CH)

    Author (Inventor): SIMONS MALCOLM J (AU)

    Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

    Applic (No,Kind,Date): DE 69029018 A 19900820

    IPC: * C12Q-001/68; C07H-021/04

    CA Abstract No: * 115(07)066222Y

    Derwent WPI Acc No: * C 91-059664

    Language of Document: German

Patent (No,Kind,Date): DE 69029018 T2 19970522

    VERFAHREN ZUM NACHWEIS VON BENACHBARTEN UND ENTFERNT LOKALISIERTEN

        ALLELEN ALS HAPLOTYPEN MITTELS INTRONSEQUENZANALYSE (German)

    Patent Assignee: GENETYPE AG (CH)

    Author (Inventor): SIMONS MALCOLM J (AU)

13

 

    Priority
(No,Kind,Date): US 398217 A 19890825; US 405499 A

        19890911; US 465863 A 19900116; US 551239 A 19900711

    Applic (No,Kind,Date): DE 69029018 A 19900820

    IPC: * C12Q-001/68; C07H-021/04

    CA Abstract No: * 115(07)066222Y

    Derwent WPI Acc No: * C 91-059664

    Language of Document: German 

GERMANY
(DE)

    Legal Status (No,Type,Date,Code,Text): 

	 	 	DE 69029018	 	P 19961205 DE REF    CORRESPONDS TO

(ENTSPRICHT)

EP 414469 P 19961205
	 	 	DE 69029018	 	P 19970522 DE 8373    TRANSLATION OF PATENT

DOCUMENT OF EUROPEAN PATENT WAS RECEIVED AND

HAS BEEN PUBLISHED (UEBERSETZUNG DER

PATENTSCHRIFT DES EUROPAEISCHEN PATENTES IST

EINGEGANGEN UND VEROEFFENTLICHT WORDEN)
	 	 	DE 69029018	 	P 19971127 DE 8364    NO OPPOSITION DURING TERM OF

OPPOSITION (EINSPRUCHSFRIST ABGELAUFEN OHNE

DASS EINSPRUCH ERHOBEN WURDE)
	 	 	DE 69029018	 	P 20030828 DE 8327    CHANGE IN THE

PERSON/NAME/ADDRESS OF THE PATENT OWNER

(AENDERUNG IN PERSON, NAMEN ODER WOHNORT DES

PATENTINHABERS)

GENETIC TECHNOLOGIES LTD., FITZROY, VICTORIA,

AU

DENMARK
(DK)

    Patent (No,Kind,Date): DK 414469 T3 19970414

        INTRONSEKVENSANALYSEFREMGANGSMAADE TIL PAAVISNING AF NABOSTILLEDE OG

            FJERNT LOKALISEREDE ALLELER SOM HAPLOTYPER (Danish)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): DK 9090309107 A 19900820

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: Danish 

EUROPEAN
PATENT OFFICE (EP)

    Patent (No,Kind,Date): EP 414469 A2 19910227

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English; French; German)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711        Applic (No,Kind,Date): EP 90309107 A 19900820

14

 

        Designated
States: (National) AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No:; 115(07)066222Y

        Derwent WPI Acc No:; C 91-059664

        Language of Document: English 

    Patent
(No,Kind,Date): EP 414469 A3 19920923

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English; French; German)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): EP 90309107 A 19900820

        Designated States: (National) AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English 

    Patent
(No,Kind,Date): EP 414469 B1 19961030

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English; French; German)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): EP 90309107 A 19900820

        Designated States: (National) AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English 

	EUROPEAN PATENT OFFICE (EP)

    Legal Status (No,Type,Date,Code,Text):
	 	 	EP 414469	 	P 19890825 EP AA    PRIORITY (PATENT APPLICATION) (PRIORITAET (PATENTANMELDUNG))

US 398217 A 19890825
	 	 	EP 414469	 	P 19890911 EP AA    PRIORITY (PATENT APPLICATION) (PRIORITAET (PATENTANMELDUNG))

US 405499 A 19890911
	 	 	EP 414469	 	P 19900116 EP AA    PRIORITY (PATENT APPLICATION) (PRIORITAET (PATENTANMELDUNG))

US 465863 A 19900116
	 	 	EP 414469	 	P 19900711 EP AA    PRIORITY (PATENT APPLICATION) (PRIORITAET (PATENTANMELDUNG))

US 551239 A 19900711
	 	 	EP 414469	 	P 19900820 EP AE    EP-APPLICATION (EUROPAEISCHE ANMELDUNG)

EP 90309107 A 19900820
	 	 	 	 	 

15

 

	 	 	EP 414469	 	P 19910227 EP AK    DESIGNATED CONTRACTING STATES IN AN APPLICATION WITHOUT SEARCH REPORT (IN EINER ANMELDUNG OHNE RECHERCHENBERICHT BENANNTE VERTRAGSSTAATEN)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE
	 	 	EP 414469	 	P 19910227 EP A2    PUBLICATION OF APPLICATION WITHOUT SEARCH REPORT (VEROEFFENTLICHUNG DER ANMELDUNG OHNE RECHERCHENBERICHT)
	 	 	EP 414469	 	P 19920923 EP AK    DESIGNATED CONTRACTING STATES IN A SEARCH REPORT (IN EINEM RECHERCHENBERICHT BENANNTE VERTRAGSSTAATEN)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE
	 	 	EP 414469	 	P 19920923 EP A3    SEPARATE PUBLICATION OF THE SEARCH REPORT (ART. 93) (GESONDERTE VEROEFFENTLICHUNG DES RECHERCHENBERICHTS (ART. 93))
	 	 	EP 414469	 	P 19930120 EP 17P    REQUEST FOR EXAMINATION FILED (PRUEFUNGSANTRAG GESTELLT) 921127
	 	 	EP 414469	 	P 19940921 EP 17Q    FIRST EXAMINATION REPORT (ERSTER PRUEFUNGSBESCHEID) 940805
	 	 	EP 414469	 	P 19961030 EP AK    DESIGNATED CONTRACTING STATES MENTIONED IN A PATENT SPECIFICATION (IN EINER PATENTSCHRIFT ANGEFUEHRTE BENANNTE VERTRAGSSTAATEN)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE
	 	 	EP 414469	 	P 19961030 EP B1    PATENT SPECIFICATION (PATENTSCHRIFT)
	 	 	EP 414469	 	P 19961030 EP REF    IN AUSTRIA REGISTERED AS: (IN AT EINGETRAGEN ALS:) AT 144797 R 19961115
	 	 	EP 414469	 	P 19961205 EP REF    CORRESPONDS TO: (ENTSPRICHT) DE 69029018 P 19961205
	 	 	EP 414469	 	P 19970127 EP ITF    IT: TRANSLATION FOR A EP PATENT FILED (IT: DEPOSITO TRADUZIONE DI BREVETTO EUROPEO) MODIANO & ASSOCIATI S.R.L.
	 	 	EP 414469	 	P 19970228 EP ET    FR: TRANSLATION FILED (FR: TRADUCTION A ETE REMISE)
	 	 	EP 414469	 	P 19970301 ES FG2A/REG DEFINITIVE PROTECTION (PROTECCION DEFINITIVA) 2095859T3
	 	 	EP 414469	 	P 19970414 DK T3/REG    TRANSLATION OF EP PATENT
	 	 	EP 414469	 	P 19971022 EP 26N    NO OPPOSITION FILED (KEIN EINSPRUCH EINGELEGT)
	 	 	EP 414469	 	P 20020101 GB IF02/REG EUROPEAN PATENT IN FORCE AS OF 2002-01-01
	 	 	EP 414469	 	P 20030314 CH PUE/REG ASSIGNMENT (UEBERTRAGUNG) GENETYPE AG -DANN AN- GENETIC TECHNOLOGIES LIMITED
	 	 	EP 414469	 	P 20030319 GB 732E/REG PROCEEDING UNDER SECTION 32 PATENTS ACT 1977 (PROC. UNDER SECT. 32 PAT. ACT 1977)
	 	 	EP 414469	 	P 20030701 EP NLS    NL: ASSIGNMENTS OF EP-PATENTS (NL: MEDEDELINGEN VAN OVERDRACHT VAN EUROPESE OCTROOIEN) GENETIC TECHNOLOGIES LIMITED
	 	 	EP 414469	 	P 20030816 ES PC2A/REG TRANSFER GRANTED (TRANSMISION CONCEDIDA)
	 	 	EP 414469	 	P 20030912 FR TP/REG    TRANSMISSION OF PROPERTY (TRANSMISSION DE PROPRIETE)

SPAIN
(ES)

    Patent (No,Kind,Date): ES 2095859 T3 19970301

        PROCEDIMIENTO DE ANALISIS DE UNA SECUENCIA DE INTRON PARA LA DETECCION

            DE ALELOS DE LOCUS ADYACENTES Y REMOTOS COMO HAPLOTIPOS. (Spanish)

        Patent Assignee: GENETYPE AG

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): ES 90309107 EP 19900820

16

 

        Addnl
Info: 0414469 EP patent valid in AT

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: Spanish

	SPAIN (ES)

    Legal Status (No,Type,Date,Code,Text):
	 	 	ES 2095859	 	P 19970301 ES FG2A    DEFINITIVE PROTECTION (PROTECCION DEFINITIVA) 414469

FINLAND
(FI)

    Patent (No,Kind,Date): FI 9004200 A0 19900824

        INTRONSEKVENSANALYSMETOD FOER DETEKTERING AV NAERLIGGANDE OCH AVLAEGSNA

            LOKUSALLELER SOM HAPLOTYPER. (Swedish)

        Patent Assignee: GENETYPE A G (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): FI 904200 A 19900824

        IPC: * C12Q

        Language of Document: Finnish; Swedish

FINLAND
(FI)

    Legal Status (No,Type,Date,Code,Text):

        FI 904200        A 19930228 FI FD        Application shelved

                        (J tetty sillens 4 kk)

GREECE
(GR)

    Patent (No,Kind,Date): GR 3022410 T3 19970430

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): GR 400134 A 19970129

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: Greek

HONG
KONG (HK)

    Patent (No,Kind,Date): HK 1008053 A1 19990430

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): HK 98107074 A 19980626

        IPC: * C12Q; C07H

17

 

        CA
Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

ISRAEL
(IL)

    Patent (No,Kind,Date): IL 95467 A0 19910630

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Assignee: GENETYPE A G

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): IL 95467 A 19900823

        IPC: * C12Q

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

    Patent (No,Kind,Date): IL 95467 A1 19950731

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG (CH)

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): IL 95467 A 19900823

        IPC: * C12Q-001/68; C07K-014/00

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

	ISRAEL (IL)

    Legal Status (No,Type,Date,Code,Text):
	 	 	IL 95467	 	P 19961031 IL FF    PATENTS GRANTED
	 	 	IL 95467	 	P 20010111 IL KB    PATENTS RENEWED
	 	 	IL 95467	 	P 20030624 IL HP    CHANGES IN PROPRIETORSHIP

JAPAN
(JP)

    Patent (No,Kind,Date): JP 3139300 A2 19910613

        METHOD OF ANALYZING INTRON SEQUENCE FOR DETECTING THE ALLEL ADJACENT TO

            GENE LOCUS AS HALO TYPE AND DISTANT THEREFROM (English)

        Patent Assignee: JIINTAIPU AG

        Author (Inventor): MARUKOMU JIEI SAIMONZU

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): JP 90224176 A 19900824

        IPC: * C12Q-001/68; C12N-015/11; A61K-048/00

        Language of Document: Japanese

    Patent (No,Kind,Date): JP 2001309796 A2 20011106

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELE AS HAPLOTYPE (English)

        Patent Assignee: GENETYPE AG

        Author (Inventor): SIMONS MALCOLM J

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

18

 

        Applic
(No,Kind,Date): JP 200192923 A 20010328

        IPC: * C12N-015/09; C12Q-001/68

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: Japanese

    Patent (No,Kind,Date): JP 3206812 B2 20010910

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): JP 90224176 A 19900824

        IPC: * C12Q-001/68; C12N-015/09

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: Japanese

NEW
ZEALAND (NZ)

    Patent (No,Kind,Date): NZ 235051 A 19920129

        DETECTING ALLELES, SPECIFICALLY THE HLA LOCUS INVOLVING DNA

            AMPLIFICATION AND ITS APPLICATION IN PATERNITY TESTING (English)

        Patent Assignee: GENETYPE AG

        Author (Inventor): SIMONS MALCOLM J

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): NZ 235051 A 19900824

        IPC: * G01N-033/50; C12N-015/10; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

SINGAPORE
(SG)

    Patent (No,Kind,Date): SG 4700747 A1 19980417

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG

        Author (Inventor): SIMONS MALCOLM J

        Priority (No,Kind,Date): US 398217 A 19890825; US 405499 A

            19890911; US 465863 A 19900116; US 551239 A 19900711

        Applic (No,Kind,Date): SG 9604155 A 19900820

        IPC: * C12Q-001/68; C07H-021/04

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

UNITED
STATES OF AMERICA (US)

    Patent (No,Kind,Date): US 5192659 A 19930309

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 465863 B2 19900116; US 405499 B2

            19890911; US 398217 B2 19890825

        Applic (No,Kind,Date): US 551239 A 19900711

        National Class: * 435006000; 435091000; 935017000; 935018000;

19

 

            935076000;
935077000; 935078000

        IPC: * C12Q-001/68; C12P-019/34

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

    Patent (No,Kind,Date): US 5612179 A 19970318

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (NZ)

        Priority (No,Kind,Date): US 949652 A 19920923; US 551239 A1

            19900711; US 465863 B2 19900116; US 405499 B2 19890911; US 398217 B2 19890825

        Applic (No,Kind,Date): US 949652 A 19920923

        Addnl Info: 5192659 19930309 Patented

        National Class: * 435006000; 435091100; 435091200; 536023100;

            536024300; 536024310; 536024330; 935077000; 935078000

        IPC: * C12Q-001/68; C12P-019/34; C07H-021/04; C12N-015/00

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

    Patent (No,Kind,Date): US 5789568 A 19980804

        HUMAN LEUKOCYTE ANTIGEN (HLA) LOCUS-SPECIFIC PRIMERS (English)

        Patent Assignee: GENETYPE AG (CH)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 682054 A 19960716; US 949652 A3

            19920923; US 551239 A1 19900711; US 465863 B2 19900116; US 405499

            B2 19890911; US 398217 B2 19890825

        Applic (No,Kind,Date): US 682054 A 19960716

        Addnl Info: 5192659 19930309 Patented

        National Class: * 536024330; 435006000; 435091200; 935008000

        IPC: * C07H-021/04; C12P-019/34; C12N-015/00

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

    Patent (No,Kind,Date): US 20030119003 AA 20030626

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

            LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG (US)

        Author (Inventor): SIMONS MALCOLM J (AU)

        Priority (No,Kind,Date): US 5626 A 20011203; US 70497 B1 19980430;

            US 682054 A1 19960716; US 949652 A3 19920923; US 551239 A1

            19900711; US 465863 B2 19900116; US 405499 B2 19890911; US 398217 B2 19890825

        Applic (No,Kind,Date): US 5626 A 20011203

        Addnl Info: 5789568 Patented; 5612179 Patented; 5192659 Patented

        National Class: * 435006000; 435091200

        IPC: * C12Q-001/68; C12P-019/34

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English

	 	 	 	 	 

20

 

	UNITED STATES OF AMERICA (US)

    Legal Status (No,Type,Date,Code,Text):
	 	 	US 5192659	 	P 19890825 US AA    PRIORITY
	 	 	US 398217	 	B2 19890825
	 	 	US 5192659	 	P 19890911 US AA    PRIORITY
	 	 	US 405499	 	B2 19890911
	 	 	US 5192659	 	P 19900116 US AA    PRIORITY
	 	 	US 465863	 	B2 19900116
	 	 	US 5192659	 	P 19900711 US AE    APPLICATION DATA (PATENT) (APPL. DATA (PATENT))
	 	 	US 551239	 	A 19900711
	 	 	US 5192659	 	P 19900711 US AS02    ASSIGNMENT OF ASSIGNOR'S INTEREST GENETYPE A.G., NEUGASSE 11, 6300 ZUG A CORP. OF SWITZERLAND; SIMONS, MALCOLM J.: 19900606
	 	 	US 5192659	 	P 19930309 US A    PATENT
	 	 	US 5192659	 	P 19940614 US CC    CERTIFICATE OF CORRECTION
	 	 	US 5612179	 	P 19890825 US AA    PRIORITY
	 	 	US 398217	 	B2 19890825
	 	 	US 5612179	 	P 19890911 US AA    PRIORITY
	 	 	US 405499	 	B2 19890911
	 	 	US 5612179	 	P 19900116 US AA    PRIORITY
	 	 	US 465863	 	B2 19900116
	 	 	US 5612179	 	P 19900711 US AA    PRIORITY
	 	 	US 551239	 	A1 19900711
	 	 	US 5612179	 	P 19920923 US AE    APPLICATION DATA (PATENT) (APPL. DATA (PATENT))
	 	 	US 949652	 	A 19920923
	 	 	US 5612179	 	P 19970318 US A    PATENT
	 	 	US 5789568	 	P 19890825 US AA    PRIORITY
	 	 	US 398217	 	B2 19890825
	 	 	US 5789568	 	P 19890911 US AA    PRIORITY
	 	 	US 405499	 	B2 19890911
	 	 	US 5789568	 	P 19900116 US AA    PRIORITY
	 	 	US 465863	 	B2 19900116
	 	 	US 5789568	 	P 19900711 US AA    PRIORITY
	 	 	US 551239	 	A1 19900711
	 	 	US 5789568	 	P 19920923 US AA    PRIORITY
	 	 	US 949652	 	A3 19920923
	 	 	US 5789568	 	P 19960716 US AE    APPLICATION DATA (PATENT) (APPL. DATA (PATENT))
	 	 	US 682054	 	A 19960716
	 	 	US 5789568	 	P 19980804 US A    PATENT
	 	 	US 20030119003	 	P 19890825 US AA    PRIORITY
	 	 	US 398217	 	B2 19890825
	 	 	US 20030119003	 	P 19890911 US AA    PRIORITY
	 	 	US 405499	 	B2 19890911
	 	 	US 20030119003	 	P 19900116 US AA    PRIORITY
	 	 	US 465863	 	B2 19900116
	 	 	US 20030119003	 	P 19900711 US AA    PRIORITY (CONTINUATION)
	 	 	US 551239	 	A1 19900711
	 	 	US 20030119003	 	P 19920923 US AA    PRIORITY (DIVISION)
	 	 	US 949652	 	A3 19920923
	 	 	US 20030119003	 	P 19960716 US AA    PRIORITY (CONTINUATION)
	 	 	US 682054	 	A1 19960716
	 	 	 	 	 

21

 

	 	 	US 20030119003	 	P 19980430 US AA    PRIORITY
	 	 	US 70497	 	B1 19980430
	 	 	US 20030119003	 	P 20011203 US AE    APPLICATION DATA (PATENT) (APPL. DATA (PATENT))
	 	 	US 5626	 	A 20011203
	 	 	US 20030119003	 	P 20030626 US A1A1    PATENT APPLICATION PUBLICATION (PRE-GRANT)

SOUTH
AFRICA (ZA)

    Patent (No,Kind,Date): ZA 9006765 A 19910626

        INTRON SEQUENCE ANALYSIS METHOD FOR DETECTION OF ADJACENT AND REMOTE

        LOCUS ALLELES AS HAPLOTYPES (English)

        Patent Assignee: GENETYPE AG

        Author (Inventor): SIMONS MALCOLM J; MALCOLM J SIMONS

        Priority (No,Kind,Date): US 398217 A 19890825

        Applic (No,Kind,Date): ZA 906765 A 19900824

        IPC: * C12N; A61K; C07H

        CA Abstract No: * 115(07)066222Y

        Derwent WPI Acc No: * C 91-059664

        Language of Document: English 

22

QuickLinks

Exhibit 4.10

LICENSE AGREEMENT

Appendix "A" Licensed Patents

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]